BioCentury
ARTICLE | Regulation

CRISPR comes of age years ahead of schedule with first diagnostic authorization

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.

May 7, 2020 1:02 PM UTC
Updated on May 9, 2020 at 1:45 AM UTC

FDA’s authorization of a CRISPR-based diagnostic for COVID-19 from Sherlock Biosciences is another step in the right direction for COVID-19 diagnostics, but it’s a much bigger win for the CRISPR technology.

It represents the first time a CRISPR-based product has been authorized for use in healthcare, and it comes years before anyone was expecting it. ...

BCIQ Company Profiles

Sherlock Biosciences Inc.